Details of the Drug
General Information of Drug (ID: DMLNTB5)
Drug Name |
TILIROSIDE
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
Tiliroside; 20316-62-5; Tribuloside; Trans-Tiliroside; UNII-15M04TXR9M; CHEMBL266564; 15M04TXR9M; CHEBI:80944; 22153-44-2; 2-Propenoic acid, 3-(4-hydroxyphenyl)-, 6'-ester with 3-(beta-D-glucopyranosyloxy)-5,7-dihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; AC1NSZRJ; SCHEMBL23597; Tiliroside, analytical standard; MEGxp0_000169; MolPort-001-740-347; ZINC17654711; BDBM50241244; AKOS015896718; MCULE-6075035042; NCGC00163634-01; LS-123660; W1685; kaempferol 3-O-(6"-O-p-coumaroyl)-glucoside; C17140
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 3 | Molecular Weight (mw) | 594.5 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 2.5 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 8 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 7 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 13 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||